Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

(2013) Anita K. Gandhi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance

(2012) A. Broyl et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

(2012) Patrick S. Ward et al.   CANCER CELL

Quantitative Proteomics for Cancer Biomarker Discovery

(2012) Shufang Liang et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

(2011) Meaghan L. Khan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Comprehensive Comparison of iTRAQ and Label-free LC-Based Quantitative Proteomics Approaches Using Two Chlamydomonas reinhardtii Strains of Interest for Biofuels Engineering

(2011) Hongxia Wang et al.   JOURNAL OF PROTEOME RESEARCH

Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial

(2011) Dominik Dytfeld et al.   LEUKEMIA & LYMPHOMA

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Global quantification of mammalian gene expression control

(2011) Björn Schwanhäusser et al.   NATURE

Abacus: A computational tool for extracting and pre-processing spectral count data for label-free quantitative proteomic analysis

(2011) Damian Fermin et al.   PROTEOMICS

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

An integrated transcriptomic and proteomic approach characterizing estrogenic and metabolic effects of 17 α-ethinylestradiol in zebrafish (Danio rerio)

(2010) Marijke De Wit et al.   GENERAL AND COMPARATIVE ENDOCRINOLOGY

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

(2010) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients

(2010) E Nicolas et al.   LEUKEMIA

Proteomic Analysis in Multiple Myeloma Research

(2010) Jana Cumova et al.   MOLECULAR BIOTECHNOLOGY

Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line

(2010) Christine Vogel et al.   Molecular Systems Biology

A guided tour of the Trans-Proteomic Pipeline

(2010) Eric W. Deutsch et al.   PROTEOMICS

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

The role of complete response in multiple myeloma

(2009) J.-L. Harousseau et al.   BLOOD

Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy

(2009) Denis M. Schewe et al.   CANCER RESEARCH

Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma

(2009) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

A Comparison of Labeling and Label-Free Mass Spectrometry-Based Proteomics Approaches

(2009) Vibhuti J. Patel et al.   JOURNAL OF PROTEOME RESEARCH

The molecular characterization and clinical management of multiple myeloma in the post-genome era

(2009) Y Zhou et al.   LEUKEMIA

Normalization and Statistical Analysis of Quantitative Proteomics Data Generated by Metabolic Labeling

(2009) Lily Ting et al.   MOLECULAR & CELLULAR PROTEOMICS

Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma

(2009) Jean-Luc Harousseau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases

(2009) Adaikkalam Vellaichamy et al.   PLoS One

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

(2008) Mauricio Pineda-Roman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Characterization of Global Yeast Quantitative Proteome Data Generated from the Wild-Type and Glucose RepressionSaccharomyces cerevisiaeStrains: The Comparison of Two Quantitative Methods

(2008) Renata Usaite et al.   JOURNAL OF PROTEOME RESEARCH